Pharmaceutical sponsor
Keymed Biosciences Co.Ltd Clinical Trials
Studies where Keymed Biosciences Co.Ltd is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 27Multiple Myeloma (MM)
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT07910903
- Testing
- CM336, CM313, Daratumumab
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Keymed Biosciences Co.Ltd
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants
This is a randomized, double-blind, placebo-parallel controlled phase I study to evaluate the safety and tolerability of single and multiple doses of CM551 in healthy participants
- Trial name
- NCT07900945
- Testing
- CM551
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced Solid Tumors
Study of CM529D1 in Participants With Advanced Solid Tumors
This is interventional study to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CM529D1 in participants with advanced solid tumors.
- Trial name
- NCT07893171
- Testing
- CM529D1
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Keymed Biosciences Co.Ltd
Healthy
Study of CM583 in Healthy Participants
This is a randomized, double-blind, placebo-controlled, single-ascending-dose Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM583 in healthy adult participants.
- Trial name
- NCT07823764
- Testing
- CM583
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis With Nasal Polyposis
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）
This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis
- Trial name
- NCT07519577
- Testing
- CM512
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Keymed Biosciences Co.Ltd
Advanced Solid Tumors
Study of CM518D1 in Patients With Advanced Solid Tumors
This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.
- Trial name
- NCT07019779
- Testing
- CM518D1
- Where
- China
- Volunteers
- 434 people
- Sponsor
- Keymed Biosciences Co.Ltd
Primary Sjögren's Syndrome (pSS)
CM336 for Active Sjogren's Syndrome Study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.
- Trial name
- NCT07642843
- Testing
- CM336
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Spontaneous Urticaria (CSU)
Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with CSU.
- Trial name
- NCT07166211
- Testing
- CM512 injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Keymed Biosciences Co.Ltd
Healthy
Study of CM383 in Healthy Subjects
This study is a Phase I, single-center, randomized, open-label, parallel-controlled study, aimed at evaluating the pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of a single dose of CM383…
- Trial name
- NCT07292688
- Testing
- CM383
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
Autoimmune Cytopenia, Immune Thrombocytopenia (ITP)
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
To evaluate the efficacy and safety of CM336 (BCMA/CD3 Bispecific Antibody) in the treatment of patients with relapsed or refractory autoimmune cytopenia
- Conditions
- Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
- Trial name
- NCT07175493
- Testing
- CM336 Injection
- Where
- 3 sites in China
- Volunteers
- 158 people
- Sponsor
- Keymed Biosciences Co.Ltd